By Fineline Cube 
Germany-based Boehringer Ingelheim released its 2024 financial report, recording group net sales of EUR 26.8 billion (USD 29.2 billion), marking a 6.1% year-on-year (YOY) increase. Human pharma sales grew by 7% to EUR 21.9 billion (USD 23.9 billion), while animal health sales rose 1.9% to EUR 4.7 billion (USD 5.1 billion).
Key Product Performance
The human pharma business was driven by strong performances from Jardiance (empagliflozin) and Ofev (nintedanib). Jardiance, used for type 2 diabetes, saw sales increase by 14.6% to EUR 8.4 billion (USD 9.2 billion). Ofev, indicated for idiopathic pulmonary fibrosis, expanded sales by 8.9% to EUR 3.8 billion (USD 4.1 billion).
Future Pipeline and R&D Investment
The company anticipates conducting over ten new Phase II and III clinical studies in the next 12 to 18 months, with several major products slated for launch within the next five years. R&D expenses for human drugs rose to EUR 5.7 billion (USD 6.2 billion), accounting for 27.6% of the net sales of this business unit. New products such as zongertinib and nerandomilast are planned for launch this year, following positive pivotal study results.
Patient Coverage and R&D Expansion
Boehringer Ingelheim reported an 8.0% increase in patient coverage over the past year, reaching 66 million patients. R&D investment increased to EUR 6.2 billion (USD 6.8 billion), representing 23.2% of the group’s net sales.-Fineline Info & Tech